Zacharoulis Dimitris, Hatzitheofilou Constantine, Athanasiou Evangelos, Zacharoulis Stergios
Department of Surgery, University of Thessally, Larisa, Greece.
Expert Rev Anticancer Ther. 2005 Aug;5(4):645-56. doi: 10.1586/14737140.5.4.645.
Hepatocellular carcinoma is a leading cause of cancer death worldwide in both adult and pediatric patients. Despite many options, no ideal treatment exists for this highly malignant tumor, and management strategies have varied accordingly. Angiogenesis, the formation of new blood vessels, is an essential component of hepatocellular carcinoma biology. Innovative approaches such as targeting the nontransformed, less resistant, tumor-supporting endothelial cells are currently under investigation in hepatocellular carcinoma. This review will focus on the current knowledge of the pathophysiology of hepatocellular carcinoma angiogenesis, as well as the reported data with angiogenesis inhibitors against hepatocellular carcinoma.
肝细胞癌是全球成人和儿童患者癌症死亡的主要原因。尽管有多种选择，但对于这种高恶性肿瘤尚无理想的治疗方法，相应地管理策略也各不相同。血管生成，即新血管的形成，是肝细胞癌生物学的重要组成部分。目前正在肝细胞癌研究中探索诸如靶向未转化、耐药性较低的肿瘤支持性内皮细胞等创新方法。本综述将聚焦于肝细胞癌血管生成病理生理学的当前知识，以及针对肝细胞癌的血管生成抑制剂的报道数据。
